- Home
- PBT vs RIGL Comparison
PBT vs RIGL Comparison
Compare PBT & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBT
- RIGL
- Stock Information
- Founded
- PBT 1980
- RIGL 1996
- Country
- PBT United States
- RIGL United States
- Employees
- PBT N/A
- RIGL N/A
- Industry
- PBT Oil & Gas Production
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- PBT Energy
- RIGL Health Care
- Exchange
- PBT Nasdaq
- RIGL Nasdaq
- Market Cap
- PBT 599.9M
- RIGL 486.4M
- IPO Year
- PBT N/A
- RIGL 2000
- Fundamental
- Price
- PBT $11.15
- RIGL $17.09
- Analyst Decision
- PBT
- RIGL Buy
- Analyst Count
- PBT 0
- RIGL 5
- Target Price
- PBT N/A
- RIGL $34.80
- AVG Volume (30 Days)
- PBT 186.1K
- RIGL 203.8K
- Earning Date
- PBT 01-01-0001
- RIGL 11-07-2024
- Dividend Yield
- PBT 5.63%
- RIGL N/A
- EPS Growth
- PBT 25.21
- RIGL N/A
- EPS
- PBT 0.78
- RIGL 0.22
- Revenue
- PBT $37,735,284.00
- RIGL $157,374,000.00
- Revenue This Year
- PBT N/A
- RIGL $48.98
- Revenue Next Year
- PBT N/A
- RIGL $14.43
- P/E Ratio
- PBT $14.36
- RIGL $77.18
- Revenue Growth
- PBT 25.46
- RIGL 21.65
- 52 Week Low
- PBT $10.14
- RIGL $7.48
- 52 Week High
- PBT $15.79
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- PBT 35.57
- RIGL 30.82
- Support Level
- PBT $10.77
- RIGL $16.68
- Resistance Level
- PBT $13.07
- RIGL $19.80
- Average True Range (ATR)
- PBT 0.59
- RIGL 1.53
- MACD
- PBT -0.26
- RIGL -1.05
- Stochastic Oscillator
- PBT 13.89
- RIGL 3.66
About PBT Permian Basin Royalty Trust
Permian Basin Royalty Trust is an express trust. The company's underlying properties include Waddell Ranch Properties in which the trust holds mineral interest as well as royalty interests in mature producing oil fields, such as Yates, Wasson, Sand Hills, East Texas, Kelly-Snyder, Panhandle Regular, N. Cowden, Todd, Keystone, Kermit, McElroy, Howard-Glasscock, Seminole and others across Texas. The company earns majority revenue in form of royalties received through its properties.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.